Practical management of cutaneous reactions to the methylphenidate transdermal system: Recommendations from a dermatology expert panel consensus meeting

Clinical Therapeutics

Volumn 30, Issue 2, 2008, Pages 326-337

  Warshaw, Erin M ^a,b   Paller, Amy S ^c   Fowler, Joseph F ^d   Zirwas, Matthew J ^e  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d University of Louisville School of Medicine   (United States)

^e THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

ADHD; cutaneous reactions; Daytrana; methylphenidate transdermal system; patch; stimulants

Indexed keywords

ALCLOMETASONE; CERAVE; CETAPHIL; CLONIDINE; CORTICOSTEROID; DESONIDE; DIPHENHYDRAMINE; EMOLLIENT AGENT; ESTRADIOL; FENTANYL; GLYCERYL TRINITRATE; HYDROCORTISONE; HYDROXYZINE; LANOLIN ALCOHOL; METHYLPHENIDATE; NEOMYCIN; NICOTINE; PETROLATUM; TESTOSTERONE; TIMOLOL MALEATE; UNCLASSIFIED DRUG; VANICREAM; VANICREAN; XIPAMIDE;

APPLICATION SITE EDEMA; APPLICATION SITE ERYTHEMA; APPLICATION SITE IRRITATION; APPLICATION SITE REACTION; APPLICATION SITE URTICARIA; ARTICLE; ATTENTION DEFICIT DISORDER; CLINICAL FEATURE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; CORTICOSTEROID THERAPY; DRUG DELIVERY SYSTEM; DRUG WITHDRAWAL; HUMAN; IRRITANT DERMATITIS; PRACTICE GUIDELINE; SCORING SYSTEM; SKIN ALLERGY; SKIN TEST;

EID: 41649096344     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.01.022     Document Type: Note

References (77)

1. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) (2000), American Psychiatric Association, Washington, DC
2. Coleman W., and Levine M. Attention deficits in adolescence: Description, evaluation, and management. Pediatr Rev 9 (1988) 287-298
3. Visser S., Lesesne C., and Perou R. National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics 119 Suppl 1 (2007) S99-S106
4. Wilens T., Faraone S., and Biederman J. Attention-deficit/hyperactivity disorder in adults. JAMA 292 (2004) 619-623
5. Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: The Multimodal Treatment Study of children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56 (1999) 1088-1096
6. Abikoff H., Hechtman L., Klein R., et al. Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. J Am Acad Child Adolesc Psychiatry 43 (2004) 802-811
7. Connor D., and Steingard R. New formulations of stimulants for attention-deficit hyperactivity disorder: Therapeutic potential. CNS Drugs 18 (2004) 1011-1030
8. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46 (2007) 894-921
9. Kalia Y., Merino V., and Guy R. Transdermal drug delivery. Clinical aspects. Dermatol Clin 16 (1998) 289-299
10. Wokovich A., Prodduturi S., Doub W., et al. Transdermal drug delivery system (TDDS) adhesion as a critical safety, efficacy and quality attribute. Eur J Pharm Biopharm 64 (2006) 1-8
11. Musel A., and Warshaw E. Cutaneous reactions to transdermal therapeutic systems. Dermatitis 17 (2006) 109-122
12. Wilkosz M., and Bogner R. Transdermal drug delivery. Part 1: Current status [US Pharmacist Web site]. http://www.uspharmacist.com/index.asp?show=article&page=8_1061.htm Accessed January 7, 2008
13. Shire Pharmaceuticals-Noven's DOT Matrix Technology [Shire US Inc. Web site]. http://www.daytrana.com Accessed January 3, 2008
14. Beltrani V., and Beltrani V. Contact dermatitis. Ann Allergy Asthma Immunol 78 (1997) 160-173
15. Löffler H., and Effendy I. Prevention of irritant contact dermatitis. Eur J Dermatol 12 (2002) 4-9
16. Effendy I., and Maibach H. Detergent and skin irritation. Clin Dermatol 14 (1996) 15-21
17. Carmichael A., and Foulds I. Allergic contact dermatitis from transdermal nitroglycerin. Contact Dermatitis 21 (1989) 113-114
18. Jordan W. Clinical evaluation of the contact sensitization potential ofa transdermal nicotine system (Nicoderm) [published correction appears in J Fam Pract. 1992;35:138]. J Fam Pract 34 (1992) 709-712
19. Welss T., Basketter D., and Schroder K. In vitro skin irritation: Facts and future. State of the art review of mechanisms and models. Toxicol In Vitro 18 (2004) 231-243
20. Wolf R., Tüzün B., and Tüzün Y. Adverse skin reactions to the nicotine transdermal system. Clin Dermatol 16 (1998) 617-623
21. Matsumura H., Oka K., Umekage K., et al. Effect of occlusion on human skin. Contact Dermatitis 33 (1995) 231-235
22. Zhai H., and Maibach H. Skin occlusion and irritant and allergic contact dermatitis: An overview. Contact Dermatitis 44 (2001) 201-206
23. Tokumura F., Ohyama K., Fujisawa H., et al. Conformability and irritancy of adhesive tapes on the skin. Contact Dermatitis 37 (1997) 173-178
24. Van der Valk P., and Maibach H. Post-application occlusion substantially increases the irritant response of the skin to repeated short-term sodium lauryl sulfate (SLS) exposure. Contact Dermatitis 21 (1989) 335-338
25. Tsai T., and Maibach H. How irritant is water? An overview. Contact Dermatitis 41 (1999) 311-314
26. Wigger-Alberti W., Iliev D., and Elsner P. Contact dermatitis due to irritation: Clinical appearance, predisposing factors and therapy. In: Adams R. (Ed). Occupational Skin Disease. 3rd ed (1999), WB Saunders, Philadelphia, Pa 1-9
27. Rietschel R., and Fowler J. The pathogenesis of allergic contact hypersensitivity. In: Rietschel R., and Fowler J. (Eds). Fisher's Contact Dermatitis. 5th ed (2001), Lippincott Williams & Wilkins, Philadelphia, Pa 1-7
28. Seidenari S., Giusti F., Pepe P., and Mantovani L. Contact sensitization in 1094 children undergoing patch testing over a 7-year period. Pediatr Dermatol 22 (2005) 1-5
29. Fyhrquist-Vanni N., Alenius H., and Lauerma A. Contact dermatitis. Dermatol Clin 25 (2007) 613-623 x
30. Warshaw E. Contact dermatitis. In: Rakel R. (Ed). Conn's Current Therapy (2000), WB Saunders, Philadelphia, Pa 830-831
31. Zeller S., and Warshaw E. Allergic contact dermatitis. Minn Med 87 (2004) 38-42
32. Kounis N., Zavras G., Papadaki P., et al. Allergic reactions to local glyceryl trinitrate administration. Br J Clin Pract 50 (1996) 437-439
33. Bircher A., Howald H., and Rufli T. Adverse skin reactions to nicotine in a transdermal therapeutic system. Contact Dermatitis 25 (1991) 230-236
34. Vincenzi C., Tosti A., Cirone M., et al. Allergic contact dermatitis from transdermal nicotine systems. Contact Dermatitis 29 (1993) 104-105
35. Dice J. Physical urticaria. Immunol Allergy Clin North Am 24 (2004) 225-246 vi
36. Rietschel R., and Fowler J. Systemic contact-type dermatitis. In: Rietschel R., and Fowler J. (Eds). Fisher's Contact Dermatitis. 5th ed (2001), Lippincott Williams & Wilkins, Philadelphia, Pa 89-101
37. Horning J., Zawada E., Simmons J., et al. Efficacy and safety of two-year therapy with transdermal clo-nidine for essential hypertension. Chest 93 (1998) 941-945
38. Pérez-Calderón R., Gonzalo-Garijo M., and Rodríguez-Nevado I. Generalized allergic contact dermatitis from nitroglycerin in a transdermal therapeutic system. Contact Dermatitis 46 (2002) 303
39. Torres V., Lopes J., and Leite L. Allergic contact dermatitis from nitroglycerin and estradiol transdermal therapeutic systems. Contact Dermatitis 26 (1992) 53-54
40. Rosenfeld A., and White W. Allergic contact dermatitis secondary to transdermal nitroglycerin. Am Heart J 108 (1984) 1061-1062
41. Holdiness M. A review of contact dermatitis associated with transdermal therapeutic systems. Contact Dermatitis 20 (1989) 3-9
42. The Transdermal Nicotine Study Group. Transdermal nicotine for smoking cessation. Six-month results from two multicenter controlled clinical trials. JAMA 266 (1991) 3133-3138
43. Hogan D., and Maibach H. Adverse dermatologic reactions to transdermal drug delivery systems. J Am Acad Dermatol 22 (1990) 811-814
44. Maibach H. Oral substitution in patients sensitized by transdermal clonidine treatment. Contact Dermatitis 16 (1987) 1-8
45. Färm G. Contact allergy to nicotine from a nicotine patch. Contact Dermatitis 29 (1993) 214-215
46. Rothschild C., and Nicol H. Allergic reaction to methylphenidate. Can Med Assoc J 106 (1972) 1064
47. Sverd J., Hurwic M., David O., and Winsberg B. Hypersensitivity to methylphenidate and dextroam-phetamine: A report of two cases. Pediatrics 59 (1977) 115-117
48. Cohen H., Nussinovitch M., and Frydman M. Fixed drug eruption caused by acetaminophen. Ann Pharmacother 26 (1992) 1596-1597
49. Confino-Cohen R., and Goldberg A. Successful desensitization of methylphenidate-induced rash. J Child Adolesc Psychopharmacol 15 (2005) 703-705
50. Weil A. Exfoliative dermatitis after medication with methylphenidate HC1 (ritalin). Ann Allergy 26 (1968) 402-404
51. Polster A., Warner M., and Camisa C. Allergic contact dermatitis from transdermal clonidine in a patient with mycosis fungoides. Cutis 63 (1999) 154-155
52. Daytrana [package insert] (2007), Shire US Inc, Wayne, Pa
53. McGough J., Wigal S., Abikoff H., et al. A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD. J Atten Disord 9 (2006) 476-485
54. Findling R., Bukstein O., Melmed R., et al. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit hyper-activity disorder. J Clin Psychiatry 69 (2008) 149-159
55. Wilens TE, Boellner SW, Lépez FA, et al. Varying the wear time of the methylphenidate transdermal system in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. In press.
56. Rugino T., Arnold L., and Kerkering J. Efficacy of transdermal methylphenidate in subjects converted from oral methylphenidate. Presented at: 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry (October 27, 2006) San Diego, Calif
57. Lopez F., Findling R., Squires L., and Livolsi M. Skin response to methylphenidate transdermal system in pediatric subjects. Presented at: Annual Meeting of the American Psychiatric Association (May 24, 2006) Toronto, Ontario, Canada
58. Boellner S., et al. A Phase I study to assess the pharmacokinetics of methylphenidate transdermal system (MTS) vs. Concerta in pediatric patients aged 6-12 with attention-deficit/hyperactivity disorder (ADHD) [protocol SPD485-101] (2004), Shire Development Inc, Wayne, Pa
59. Boellner S., et al. A Phase I study to assess the relative bioavailability and pharmacokinetics of methylphenidate transdermal system (MTS) vs. Concerta in pediatric patients aged 6-12 with attention-deficit/hyperactivity disorder (ADHD) [protocol SPD485-102] (2005), Shire Development Inc, Wayne, Pa
60. Wigal S., et al. A Phase II, randomized, double-blind, multi-center, placebo-controlled, dose optimization, analog classroom, crossover study designed to assess the time course of treatment effect, tolerability and safety of methylphenidate transdermal system (MTS) in pediatric patients aged 6-12 with attention-deficit/hyperactivity disorder (ADHD) [protocol SPD485- 201] (2005), Shire Development Inc, Wayne, Pa
61. Findling R., et al. A Phase III, randomized, double-blind, multi-center, parallel-group, placebo-controlled, dose optimization study, designed to evaluate the safety and efficacy of methylphenidate transdermal system (MTS) vs. Concerta in pediatric patients aged 6-12 with attention-deficit/hyperactivity disorder (ADHD) [protocol SPD485-302] (2005), Shire Development Inc, Wayne, Pa
62. Findling R., et al. A Phase III, multi-center, open-label study of methylphenidate transdermal system (MTS) in pediatric patients aged 6-12 with attention-deficit/hyperactivity disorder (ADHD) [protocol SPD485-303] (2007), Shire Development Inc, Wayne, Pa
63. Wilens T. A Phase IIB, randomized, double-blind, multi-center, placebo-controlled, dose-optimization, 3-way cross-over, analog classroom study to assess the efficacy, duration of effect, tolerability and safety of 4- and 6-hour wear times of methyl-phenidate transdermal system (MTS) in pediatric subjects aged 6-12 with attention-deficit/hyperactivity disorder (ADHD) [protocol SPD485-304] (2006), Shire Development Inc, Wayne, Pa
64. Arnold L. A prospective, open-label, multi-center study evaluating the safety and tolerability of methylphenidate transdermal system (MTS) in children aged 6-12 previously treated with extended-release methylphenidate product [protocol SPD485-305] (2006), Shire Development Inc, Wayne, Pa
65. Shire overview of dermatological responses (2006), Shire Development Inc, Wayne, Pa
66. Wilens T. A Phase IV, Multi-center, open-label study of Daytrana (methylphenidate transdermal system [MTS]) to characterize the dermal reactions in pediatric patients aged 6-12 with attention deficit/hyperactivity disorder (ADHD) [protocol SPD485-411] (2007), Shire Development Inc, Wayne, Pa
67. Agner T., and Held E. Skin protection programmes. Contact Dermatitis 47 (2002) 253-256
68. Arnold L., Lindsay R., López F., et al. Treating attention-deficit/hyperactivity disorder with a stimulant transdermal patch: The clinical art. Pediatrics 120 (2007) 1100-1106
69. Effendy I., and Maibach H. Surfactants and experimental irritant contact dermatitis. Contact Dermatitis 33 (1995) 217-225
70. Löffler H., Kampf G., Schmermund D., and Maibach H. How irritant is alcohol?. Br J Dermatol 157 (2007) 74-81
71. Fartasch M. Ultrastructure of the epidermal barrier after irritation. Microsc Res Tech 37 (1997) 193-199
72. Berardesca E., Barbareschi M., Veraldi S., and Pimpinelli N. Evaluation of efficacy of a skin lipid mixture in patients with irritant contact dermatitis, allergic contact dermatitis or atopic dermatitis: A multicenter study. Contact Dermatitis 45 (2001) 280-285
73. De Paépe K., Hachem J., Vanpee E., et al. Beneficial effects of a skin tolerance-tested moisturizing cream on the barrier function in experimentally-elicited irritant and allergic contact dermatitis. Contact Dermatitis 44 (2001) 337-343
74. McGriff N., Csako G., Kabbani M., et al. Treatment options for pharmacotherapy. Allergy Asthma Proc 21 (2001) 1425-1435
75. Militello G., Jacob S., and Crawford G. Allergic contact dermatitis in children. Curr Opin Pediatr 18 (2006) 385-390
76. Bruckner A., and Weston W. Allergic contact dermatitis in children: A practical approach to management. Skin Therapy Lett 7 (2002) 3-5
77. Levin C., and Maibach H. An overview of the efficacy of topical corticosteroids in experimental human nickel contact dermatitis. Contact Dermatitis 43 (2000) 317-321